title: Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-β1 and HIF-1α in Ang II-mediated fibrosis after myocardial infarction.
abstract: Transforming growth factor (TGF)-β1 is a known factor in angiotensin II (Ang II)-mediated cardiac fibrosis after myocardial infarction (MI). Hypoxia inducible factor-1 (Hif-1α) was recently demonstrated to involve in the tissue fibrosis and influenced by Ang II. However, whether Hif-1α contributed to the Ang II-mediated cardiac fibrosis after MI, and whether interaction or synergetic roles between Hif-1α and TGF-β pathways existed in the process was unclear. In vitro, cardiac cells were incubated under hypoxia or Ang II to mimic ischaemia. In vivo, valsartan was intravenously injected into Sprague-Dawley rats with MI daily for 1 week; saline and hydralazine (another anti-hypertensive agent like valsartan) was used as control. The fibrosis-related proteins were detected by Western blotting. Cardiac structure and function were assessed with multimodality methods. We demonstrated in vitro that hypoxia would induce the up-regulation of Ang II, TGF-β/Smad and Hif-1α, which further induced collagen accumulation. By blocking with valsartan, a blocker of Ang II type I (AT1) receptor, we confirmed that the up-regulation of TGF-β/Smad and Hif-1α was through the Ang II-mediated pathway. By administering TGF-β or dimethyloxalylglycine, we determined that both TGF-β/Smad and Hif-1α contributed to Ang II-mediated collagen accumulation and a synergetic effect between them was observed. Consistent with in vitro results, valsartan significantly attenuated the expression of TGF-β/Smad, Hif-1α and fibrosis-related protein in rats after MI. Heart function, infarcted size, wall thickness as well as myocardial vascularization of ischaemic hearts were also significantly improved by valsartan compared with saline and hydralazine. Our study may provide novel insights into the mechanisms of Ang II-induced cardiac fibrosis as well as into the cardiac protection of valsartan.
authors.affiliation: Department of Cardiothoracic Surgery, The Civil Aviation General Hospital, Chaoyang District, Beijing, China.
authors.forename: Xizhong
authors.initials: X
authors.lastname: Sui
authors.affiliation: Department of Cardiothoracic Surgery, The Civil Aviation General Hospital, Chaoyang District, Beijing, China.
authors.forename: Hongchao
authors.initials: H
authors.lastname: Wei
authors.affiliation: The Wulanchabu Medical College, Jining, Inner Mongolia, China.
authors.forename: Dacheng
authors.initials: D
authors.lastname: Wang
mesh_terms: D000804:Angiotensin II; D000818:Animals; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003094:Collagen / Q000378:metabolism; D005355:Fibrosis; D006334:Heart Function Tests / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D017207:Rats, Sprague-Dawley; D053773:Transforming Growth Factor beta1 / Q000378:metabolism*; D014463:Ultrasonography; D000068756:Valsartan / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D002316:Cardiotonic Agents; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D053773:Transforming Growth Factor beta1; D000804:Angiotensin II; D000068756:Valsartan; D003094:Collagen; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9
keywords: Hif-1α; TGF-β1; fibrosis; myocardial infarction; valsartan
references.citation: Tissue Eng. 2007 Jun;13(6):1325-31
references.pmid: 17518749
references.citation: J Gastroenterol Hepatol. 2006 Aug;21(8):1250-6
references.pmid: 16872305
references.citation: Clin Sci (Lond). 2010 Oct;119(7):273-82
references.pmid: 20446923
references.citation: Am J Transplant. 2005 Sep;5(9):2185-92
references.pmid: 16095497
references.citation: Zhonghua Yi Xue Za Zhi. 2007 Feb 6;87(6):366-70
references.pmid: 17456374
references.citation: Hypertension. 2012 Mar;59(3):580-6
references.pmid: 22232134
references.citation: Clin Cardiol. 2010 Mar;33(3):149-56
references.pmid: 20235205
references.citation: J Mol Cell Cardiol. 2000 Oct;32(10):1805-19
references.pmid: 11013125
references.citation: Lancet. 2007 Apr 28;369(9571):1431-9
references.pmid: 17467513
references.citation: Cardiovasc Res. 2002 Feb 15;53(3):728-39
references.pmid: 11861043
references.citation: Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Oct;35(10):1048-56
references.pmid: 21051829
references.citation: Endocr Relat Cancer. 2012 Feb;19(1):13-27
references.pmid: 22009797
references.citation: Nat Rev Cancer. 2006 May;6(5):392-401
references.pmid: 16572188
references.citation: J Pathol. 2003 Jul;200(4):500-3
references.pmid: 12845617
references.citation: Cardiovasc Res. 2014 Jun 1;102(3):460-8
references.pmid: 24623277
references.citation: Int J Cardiol. 2011 Aug 18;151(1):18-33
references.pmid: 20546954
references.citation: Biomaterials. 2012 Apr;33(11):3093-106
references.pmid: 22265788
references.citation: Am J Nephrol. 2003 Sep-Oct;23(5):300-6
references.pmid: 12904684
references.citation: Exp Mol Pathol. 2009 Dec;87(3):212-8
references.pmid: 19527710
references.citation: Tissue Eng Part A. 2010 Apr;16(4):1303-15
references.pmid: 19905874
references.citation: Heart Fail Rev. 2014 Mar;19(2):173-85
references.pmid: 23124941
references.citation: J Hypertens. 2007 Aug;25(8):1633-42
references.pmid: 17620960
references.citation: J Heart Lung Transplant. 2010 Aug;29(8):881-7
references.pmid: 20466563
references.citation: Semin Nephrol. 1997 Sep;17(5):455-66
references.pmid: 9316214
references.citation: Clin Invest Med. 2005 Jun;28(3):118-26
references.pmid: 16021985
references.citation: Nat Med. 2012 Jul;18(7):1028-40
references.pmid: 22772564
references.citation: Biomed Res Int. 2014;2014:627380
references.pmid: 25401104
references.citation: Int J Mol Med. 2011 Sep;28(3):449-54
references.pmid: 21667015
references.citation: Diabetes Res Clin Pract. 2012 Jul;97(1):125-31
references.pmid: 22377232
references.citation: Hypertens Res. 2008 Oct;31(10):1835-42
references.pmid: 19015589
references.citation: Evid Based Cardiovasc Med. 2005 Jun;9(2):115-6
references.pmid: 16380005
references.citation: Cytokine. 2011 Feb;53(2):223-30
references.pmid: 21129996
references.citation: Exp Cell Res. 2012 Oct 1;318(16):2105-15
references.pmid: 22749815
references.citation: N Engl J Med. 2002 Apr 11;346(15):1173-4
references.pmid: 11951861
references.citation: Brain Res. 2012 Aug 30;1471:46-55
references.pmid: 22820296
references.citation: Vasc Health Risk Manag. 2007;3(4):425-30
references.pmid: 17969373